INTS (Intensity Therapeutics) Short Interest


INTS Intensity Therapeutics Inc INTS
28 GF Score
Price $4.09
! 1 Warning Sign
View Full Analysis

What is Intensity Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

INTS vs BRTX, KPRX, ERNA: Short Interest Comparison

For the Biotechnology subindustry, Intensity Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intensity Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intensity Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Intensity Therapeutics's Short Interest falls into.


INTS
28GF Score
Intensity Therapeutics Inc INTS
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intensity Therapeutics Business Description

Address 1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
28GF Score

Get the complete analysis for INTS

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.09
Price